OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world leader in listeria-based cancer ...
Fibocom introduces an LTE Cat.1 bis module designed to support single-SKU global IoT deployments with low power and broad band coverage.
The super jumbo airplane touched down bringing down the curtain on a remarkable 30-year career as the backbone of Airbus’ ...
Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncolo ...
The elite consulting firm appears to be signalling that juniors must combine AI fluency with sound judgment. There is, however, a tension in this shift.
Fibocom (300638.SZ | 0638.HK), a global leader in wireless communication modules and edge AI solutions, today announced the launch of its global LTE Cat.1 bis module, LE271-GL, providing IoT devices ...
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today unveiled its SRG091X and SRG093X series modules at CES in Las Vegas, delivering integrated CPU, memory and wireless ...
The All Progressives Congress has reaffirmed its commitment to President Bola Tinubu’s 2027 re-election bid, assuring that victory is certain, even as former presidential candidate Peter Obi dumped ...
Antibody drug conjugates (ADCs) mark a new era in targeted cancer therapy, delivering potent cytotoxic chemotherapy via monoclonal antibodies directly into the tumor cells — an era with potentially ...
The SLogic16U3 is a compact, low-cost USB 3.0 logic analyzer with up to 3.2 Gbps bandwidth and 16 input channels, designed for debugging, reverse-engineering, and verifying digital circuits and ...
From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the ...
ADC usage in breast cancer treatment increased 3.7-fold from 2021 to 2023, with significant reductions in median time to treatment. Older women experience lower ADC treatment rates and longer delays ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results